Search results
Biogen Pharmachem Industries - Closure of Trading Window
CNBC Awaaz· 17 hours agoBiogen Pharmachem Industries - Closure of Trading Window
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
Pharmaceutical Technology· 3 days agoAs Eli Lilly’s Kisunla (donanemab) enters the Alzheimer's treatment space, its leading competitor ...
Biogen Pharmachem Industries Ltd Stock Price: Biogen Pharma Share Price Today | India Infoline
India Infoline· 3 days agoBiogen Pharmachem Industries Ltd was formerly incorporated as Wellworth Overseas Limited in July, 1995. The name of the Company was changed to Sun Techno Overseas Limited ...
Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Pharmaceutical Technology· 4 days agoEisai and Biogen must now brace for competition as the US Food and Drug Administration (FDA) has...
Lilly drug for Alzheimer’s approved by FDA
BioPharma Dive· 4 days agoThe drug, which Lilly will sell as Kinsunla, carries a warning for the risk of a certain kind of imaging abnormality that can be serious in rare cases.
Delaying Dementia? New drug just approved
WDHN Dothan· 4 days agoU.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the...
Eli Lilly Alzheimer's drug approved by US FDA
Hindustan Times· 4 days agoThe U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early Alzheimer's, making it the second therapy for slowing...
Japan's Eisai developing dementia drug for US market - ET HealthWorld | Pharma
The Economic Times· 6 days agoEisai already has a dementia drug on the U.S. market called Leqembi, co-developed with U.S. peer ...
Eli Lilly Alzheimer's drug approved by US FDA - ET HealthWorld | Pharma
The Economic Times· 3 days agoLondon: The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early...
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
Pharmaceutical Technology· 2 days agoKisunla is the second disease-modifying therapy (DMT) to reach the AD market in the US, providing...
